Published online Sep 15, 1997. doi: 10.3748/wjg.v3.i3.165
Revised: December 22, 1996
Accepted: January 30, 1997
Published online: September 15, 1997
AIM: To observe the effect of double bullet immunotargeting therapy with chemotherapy and internal radiotherapy on primary liver cancer.
METHODS: The polyclonal horse antibody against human AFP (anti-AFPAb) and the monoclonal murine antibody against human AFP (anti-AFPMcAb) were used as carriers, and 131I and mitomycin C (MMC) were used as warheads to form double bullet, i.e. 131I anti-AFPMcAb-MMC (double bullet 1) and 131I anti-AFPAb-MMC (double bullet 2) prepared using the modified chloramine T method. Double bullet targeting therapy was administered by intravenous drip once a month in 31 patients (treatment group) with unresectable primary liver cancer. Among them, 4, 17 and 10 patients were administered 1, 2 and 3 times, and the median radiation dose (MBq/case) was 193.5 ± 37.74; 651.9 ± 232.4, and 992.0 ± 230.5 respectively.
METHODS: Tumor shrinkage, decrease in AFP, and 1 and 2 -year survival rates were significantly higher than the control groups who received transarterial infusion (TAI) or transarterial chemoembolization (TACE) at the same time (50.0%, 15/30 vs 30.0%, 9/30, P < 0.05; 66.7%, 18/27 vs 28.0%, 7/25, P < 0.01 and 50.0%, 34.0% vs 33.0%, 3.3%, P < 0.01, respectively). Furthermore, the tumor progression rate (10%) in the treatment group was significantly lower than that of the control group (40.0%, P < 0.01).
CONCLUSION: Double bullet target therapy is more effective than traditional therapies due to the synergistic effects of the antibody, radioisotope, and anticancer agents, which together, enhance tumor killing.
- Citation: Wu YD, Zhou DN, Gang YQ, Hu XH, Li ZG, Song XQ, He HP, Yang KZ, Huang BY. Double-bullet radioimmunotargeting therapy in 31 primary liver cancer patients. World J Gastroenterol 1997; 3(3): 165-165
- URL: https://www.wjgnet.com/1007-9327/full/v3/i3/165.htm
- DOI: https://dx.doi.org/10.3748/wjg.v3.i3.165
Original title:
S- Editor: Filipodia L- Editor: Jennifer E- Editor: Hu S